NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
NanoViricides, Inc. announced significant progress in its antiviral research program, with CEO Dr. Anil Diwan revealing during a video interview with Proactive available at https://youtu.be/m_3Yk4_832E that the company's lead candidate NV-387 has demonstrated potent anti-Measles activity. The findings come at a critical time when Measles cases are resurging globally, and no approved treatments currently exist for the viral infection.
According to Dr. Diwan, NV-387 showed strong anti-Measles activity in both cell culture and humanized animal models, extending survival by 130% and protecting lung tissue during severe infection stages. These results highlight the drug's broad-spectrum potential beyond its primary development targets. The company's platform technology and programs are based on the TheraCour nanomedicine technology licensed from TheraCour Pharma, Inc., with NanoViricides holding exclusive perpetual licenses for several viral disease treatments.
The clinical significance of these findings cannot be overstated, as Measles remains a leading cause of vaccine-preventable death in children worldwide. Recent outbreaks have highlighted the urgent need for therapeutic options, particularly for vulnerable populations and in cases where vaccination is not possible. NV-387 has already completed Phase I human trials with no reportable adverse events and is advancing to Phase II trials for MPox, positioning the company to support FDA emergency use applications and investigator-initiated INDs for urgent Measles cases.
NanoViricides' business model involves licensing technology from TheraCour Pharma Inc. for specific antiviral applications, as established at its foundation in 2005. The company's latest news and updates are available in its newsroom at https://ibn.fm/NNVC. Beyond Measles and MPox, the company is developing NV-387 as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, while also advancing NV-HHV-1 for Shingles treatment.
The broader implications of successful Measles treatment development extend beyond immediate patient care. Effective therapeutics could complement vaccination efforts, provide options for immunocompromised individuals, and potentially reduce transmission in outbreak settings. However, the company acknowledges the inherent risks of drug development, noting that the path to typical pharmaceutical product approval is extremely lengthy and requires substantial capital, with no assurance that preclinical success will translate to clinical effectiveness.
NanoViricides maintains additional development programs against numerous viral diseases including oral and genital Herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company's approach represents a significant shift in antiviral strategy, focusing on broad-spectrum capabilities that could address multiple viral threats with a single therapeutic platform.